Short answer
Bicara Therapeutics Inc. (BCAX) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$55M
- −102.4% YoY · +1.4% QoQ
- EPS (diluted)
- −$0.80
- −60.0% YoY · +14.0% QoQ
Source: XBRL data from the Bicara Therapeutics Inc. (BCAX) Q2 2026 10-Q on SEC EDGAR. USD.
Bicara Therapeutics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved for sale
- Net loss $55.4M vs $27.4M YoY; operating margin not applicable with no revenue
- R&D expenses $45.8M vs $24.8M, led by clinical operations and development at $21.4M
- Cash, cash equivalents and marketable securities $497.3M at June 30, 2026; February offering netted $161.8M
- Cash runway into first half of 2029; substantial enrollment expected by end-2026, with interim analysis targeted for mid-2027
Risk Factors
- No material-change statement; carried-forward risks reflect clinical-stage status and no commercial revenue
- Regulatory risk: FDA, Health Canada, or EMA may require additional trials, delaying ficerafusp alfa approval
- Near-term clinical risk: Phase 2/3 FORTIFI-HN01 failure could materially harm development plans
- Competitive risk: Keytruda and other HNSCC therapies may establish stronger market positions before launch
- Liquidity risk: $497.3 million cash, equivalents, and securities expected to fund operations into first half of 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bicara Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.